Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | FFAR2 | O15552 | 6/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590331 | 0.80 | PTGS2 (0.61) | BRD4FFAR2ADRB2POLBMEN1 | |
| SCHEMBL598280 | 0.80 | PTGS2 (0.61) | BRD4FFAR2ADRB2POLBMEN1 | |
| SCHEMBL621292 | 0.80 | BRD4 (0.50) | BRD4FFAR2ADRB2HDAC4HDAC7 | |
| SCHEMBL12225982 | 0.80 | BRD4 (0.61) | BRD4FFAR2ADRB2HDAC4HDAC7 | |
| SCHEMBL15695554 | 0.80 | BRD4 (0.61) | BRD4FFAR2ADRB2HDAC4HDAC7 | |
| SCHEMBL24519245 | 0.80 | ALOX5 (0.46) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL121108 | 0.80 | PTGS2 (0.61) | BRD4FFAR2ADRB2POLBMEN1 | |
| Hydrochloric Acid SCHEMBL5846545 | 0.78 | PTGS2 (0.59) | BRD4FFAR2POLBMEN1KMT2A | |
| SCHEMBL21348450 | 0.78 | GRM7 (0.45) | HDAC4HDAC7HDAC5SMN1; SMN2MEN1 | |
| SCHEMBL607802 | 0.78 | EPHX1 (0.58) | BRD4FFAR2ADRB2HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | FAP, FIBP, FGFR1 | BRD4 1133/4885FFAR2 1025/4885ADRB2 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.